InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis April 23, 2019 FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... August 18, 2023 The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... March 9, 2021 Load more HOT NEWS Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations...
